Viscoelastic Tests-Guided Therapy In Liver Transplantation (VETLT)
Primary Purpose
Liver Transplant; Complications, Bleeding, Hemostatic Disorder
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Usual Care
Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
Sponsored by
About this trial
This is an interventional treatment trial for Liver Transplant; Complications focused on measuring Liver Transplantation, Blood Coagulation Disorders, Blood Transfusion, Hemostasis, Thromboelastometry
Eligibility Criteria
Inclusion Criteria:
- Deceased Donor Liver Transplantation
- Chronic Liver Disease
Exclusion Criteria:
- Acute Liver Failure
- Combined Transplantation
- Re-Transplantation is Less Than 30 Days After the First Transplant
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Usual Care (Before)
Thromboelastometry-Guided Therapy (After)
Arm Description
No Thromboelastometry No Synthetic Factor Concentrates Usual Care
Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
Outcomes
Primary Outcome Measures
Need of Any Blood Products Transfusion
Collapsed composite of need of any transfusion of blood product during surgery and in the first 48 hours in the postoperative, including the need of RBC, FFP, cryoprecipitate and/or platelets.
Secondary Outcome Measures
Use of Synthetic Factor Concentrates or Antifibrinolytic
Any use of synthetic factor concentrates or antifibrinolytic
Clinical Complications Related to the Procedure
Defined as: 1) Upper digestive hemorrhage; 2) Arterial thrombosis; 3) Infection; and/or 4) Any thromboembolic event
Duration of Mechanical Ventilation
Duration of mechanical ventilation in the post-operative period
ICU Length of Stay
Duration of stay in the intensive care unit
Hospital Length of Stay
Duration of stay in the hospital
In-Hospital Mortality
Any death during hospitalization
Full Information
NCT ID
NCT03756948
First Posted
November 16, 2018
Last Updated
November 27, 2018
Sponsor
Hospital Israelita Albert Einstein
1. Study Identification
Unique Protocol Identification Number
NCT03756948
Brief Title
Viscoelastic Tests-Guided Therapy In Liver Transplantation
Acronym
VETLT
Official Title
Association Between Viscoelastic Tests-Guided Therapy With Synthetic Factor Concentrates And Allogenic Blood Transfusion In Liver Transplantation: A Before-After Study
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
January 1, 2007 (Actual)
Primary Completion Date
October 30, 2015 (Actual)
Study Completion Date
January 1, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Israelita Albert Einstein
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
BACKGROUND: Perioperative bleeding and transfusion are important causes of morbidity and mortality in patients undergoing liver transplantation. The aim of this study is to assess whether viscoelastic tests-guided therapy with the use of synthetic factor concentrates impact transfusion rates of hemocomponents in adult patients undergoing liver transplantation.
METHODS: This is an interventional before-after comparative study. Patients undergoing liver transplantation before the implementation of a protocol using thromboelastometry and synthetic factor concentrates were compared to patients after the implementation. Primary outcome was transfusion of any hemocomponents. Secondary outcomes included: transfusion of red blood cells (RBC), fresh frozen plasma (FFP), cryoprecipitate or platelets, clinical complications, length of stay and in-hospital mortality.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Transplant; Complications, Bleeding, Hemostatic Disorder
Keywords
Liver Transplantation, Blood Coagulation Disorders, Blood Transfusion, Hemostasis, Thromboelastometry
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
237 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Usual Care (Before)
Arm Type
Active Comparator
Arm Description
No Thromboelastometry No Synthetic Factor Concentrates Usual Care
Arm Title
Thromboelastometry-Guided Therapy (After)
Arm Type
Experimental
Arm Description
Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
Intervention Type
Other
Intervention Name(s)
Usual Care
Intervention Description
Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components
Intervention Type
Other
Intervention Name(s)
Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
Intervention Description
Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
Primary Outcome Measure Information:
Title
Need of Any Blood Products Transfusion
Description
Collapsed composite of need of any transfusion of blood product during surgery and in the first 48 hours in the postoperative, including the need of RBC, FFP, cryoprecipitate and/or platelets.
Time Frame
48 Hours
Secondary Outcome Measure Information:
Title
Use of Synthetic Factor Concentrates or Antifibrinolytic
Description
Any use of synthetic factor concentrates or antifibrinolytic
Time Frame
48 Hours
Title
Clinical Complications Related to the Procedure
Description
Defined as: 1) Upper digestive hemorrhage; 2) Arterial thrombosis; 3) Infection; and/or 4) Any thromboembolic event
Time Frame
Third days or until hospital discharge, whichever occurs first
Title
Duration of Mechanical Ventilation
Description
Duration of mechanical ventilation in the post-operative period
Time Frame
Third days or until hospital discharge, whichever occurs first
Title
ICU Length of Stay
Description
Duration of stay in the intensive care unit
Time Frame
Third days or until ICU discharge, whichever occurs first
Title
Hospital Length of Stay
Description
Duration of stay in the hospital
Time Frame
Third days or until hospital discharge, whichever occurs first
Title
In-Hospital Mortality
Description
Any death during hospitalization
Time Frame
Third days or until hospital discharge, whichever occurs first
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Deceased Donor Liver Transplantation
Chronic Liver Disease
Exclusion Criteria:
Acute Liver Failure
Combined Transplantation
Re-Transplantation is Less Than 30 Days After the First Transplant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ary Serpa Neto, MD, MSc, PhD
Organizational Affiliation
Physician and Researcher
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Raffael PC Zamper, MD
Organizational Affiliation
Raffael
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
23478547
Citation
Rana A, Petrowsky H, Hong JC, Agopian VG, Kaldas FM, Farmer D, Yersiz H, Hiatt JR, Busuttil RW. Blood transfusion requirement during liver transplantation is an important risk factor for mortality. J Am Coll Surg. 2013 May;216(5):902-7. doi: 10.1016/j.jamcollsurg.2012.12.047. Epub 2013 Mar 9.
Results Reference
background
PubMed Identifier
26819521
Citation
Hartmann M, Szalai C, Saner FH. Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment. World J Gastroenterol. 2016 Jan 28;22(4):1541-50. doi: 10.3748/wjg.v22.i4.1541.
Results Reference
background
PubMed Identifier
15784122
Citation
Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005 Apr;27(2):81-90. doi: 10.1111/j.1365-2257.2005.00681.x.
Results Reference
background
PubMed Identifier
22914710
Citation
Weber CF, Gorlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, Zacharowski K. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012 Sep;117(3):531-47. doi: 10.1097/ALN.0b013e318264c644.
Results Reference
background
PubMed Identifier
20832550
Citation
Wang SC, Shieh JF, Chang KY, Chu YC, Liu CS, Loong CC, Chan KH, Mandell S, Tsou MY. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc. 2010 Sep;42(7):2590-3. doi: 10.1016/j.transproceed.2010.05.144.
Results Reference
background
PubMed Identifier
30579327
Citation
Zamper RPC, Amorim TC, Queiroz VNF, Lira JDO, Costa LGV, Takaoka F, Juffermans NP, Neto AS. Association between viscoelastic tests-guided therapy with synthetic factor concentrates and allogenic blood transfusion in liver transplantation: a before-after study. BMC Anesthesiol. 2018 Dec 22;18(1):198. doi: 10.1186/s12871-018-0664-8.
Results Reference
derived
Learn more about this trial
Viscoelastic Tests-Guided Therapy In Liver Transplantation
We'll reach out to this number within 24 hrs